Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 29

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 29
---
-urinary

HCC Hepatocellular carcinoma

HER2 / +/- /low /m Human epidermal growth factor receptor 2 / positive / negative / low expression / gene mutation

HR / + / - Hormone receptor / positive / negative

HSCT-TMA Hematopoietic stem cell transplantation-associated thrombotic microangiopathy

ICS Inhaled corticosteroid

IHC Immunohistochemistry

IL-5 Interleukin-5

ISH In situ hybridisation

JP Japan

LABA Long-acting beta-agonist

LDH Lactic dehydrogenase

LDL-C Low-density lipoprotein cholesterol

MCL Mantle cell lymphoma

MIBC Muscle-invasive bladder cancer

n/m Growth rate not meaningful

NF1-PN Neurofibromatosis type 1 with plexiform neurofibromas

NRDL National reimbursement drug list

NSCLC Non-small cell lung cancer

OS Overall survival

PARP Poly ADP ribose polymerase

pCR Pathologic complete response

PFS Progression free survival

PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha gene

PNH Paroxysmal nocturnal haemoglobinuria

PTEN Phosphatase and tensin homologue gene

R&D Research and development

ROW Rest of world

SCLC Small cell lung cancer

SG&A Sales, general and administration

SGLT2 Sodium-glucose cotransporter 2

SLL Small lymphocytic lymphoma

THP A treatment regimen: docetaxel, trastuzumab and pertuzumab

VBP Value based procurement

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date: 29 April 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |